Find clinical trials

Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

The technological intervention underpinning the Medly Program is the digital therapeutic Medly20, a smartphone app with a built-in rules-based algorithm that provides heart failure (HF) patients with personalized self-care feedback based on daily entry of physiological parameters (e.g., weight, blood pressure, and heart rate) and symptoms from home, and continuous monitoring by their healthcare team through an integrated clinician dashboard. The clinical effectiveness and implementation of Medly have been studied through randomised controlled trials, feasibility trials, and observation studies over the past decade, but only in Ontario, Canada. The primary research aim is to determine the implementation factors and implementation outcomes of Medly for HF management at participating national and international hospitals in Alberta (Canada), Australia, and the United Kingdom.

Researchers are looking for new ways to treat certain advanced or metastatic solid tumours. The goal of this study is to learn about the safety, tolerability, pharmacokinetics, and efficacy of MK-4716 as monotherapy and part of combination therapy in participants with KRAS-altered tumours.

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread. HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2. Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles. Metastatic means the cancer has spread to other parts of the body. Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. This study consists of a 16-week Double-blind Period and a 100-week Longterm Extension (LTE) composed of a 40-week Main Extension and a 60-week Optional Extension. Each participant will participate in the study for approximately 135 weeks from the time the participant provides documented informed consent through the final contact. (including screening & follow up). There will be 147 participants across 70 centers worldwide.

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT).